The Senate recently voted to pass the U.S. Food and Drug Administration Reauthorization Act of 2017 (FDARA) following the June passage of the legislation by the House. FDARA contains reauthorizations of the user fee agreements that support the FDA’s evaluation of prescription drugs, medical devices, generic drugs and biosimilar products. The legislation was sent to the president’s desk where it awaits his signature. Designed to provide essential resources that improve efficiency in the review process, the user fee agreements extend through fiscal year 2022.

Keywords: Drugs, Generic, United States Food and Drug Administration, Prescription Drugs, Health Resources

< Back to Listings